Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Pfizer in talks to acquire Seagen in deal likely valued at more than $30B

Por: Fox Business Business February 27, 2023

thumbnail

JPMorgan Chase CEO Jamie Dimon discusses the state of the company and macroeconomic picture in an exclusive interview on 'Mornings with Maria.' Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the for a big drug company aimed at adding a promising class of targeted cancer therapies. The talks are at an early stage, and there is no guarantee there will be a deal, the people said. A... + full article



Similar News

Fact Check: Were the Grammys sponsored by Pfizer?

Newsweek USA Business February 06, 2023

thumbnailPfizer's involvement with the 2023 Grammy Awards sparked speculation online, with some viewers wondering how much input the pharmaceutical company had.The annual music ceremony was held at the Crypto.com Arena in Los Angeles, California on Sunday night, with Beyoncé... + más

Here's how to watch the 2023 Grammys on iPhone, iPad, Apple TV, and more | 9to5Mac

Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy. | MarketWatch


Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

MarketWatch USA Business February 04, 2023

thumbnailPfizer stock, too, has fallen out of favor, along with other Covid plays. At $44, it’s down 15% this year, making it one of the worst performers in the index. And it’s 30% below its late 2021 peak, badly trailing the rest of the drug group.   Now looks like the time to buy... + más

Fact Check: Were the Grammys sponsored by Pfizer? | Newsweek

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC


Pfizer accused of obscene COVID profits after posting record revenues

Newsweek USA Business February 02, 2023

thumbnailPharmaceutical giant Pfizer has been accused of making an obscene profit from the coronavirus pandemic after it posted record revenue of more than $100 billion for 2022, a rise of 23 percent on the previous year.The company's COVID products Comirnaty, an mRNA vaccine and... + más

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC


Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

CNBC USA Health December 06, 2022

thumbnailVials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más

Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate

Moderna is suing Pfizer over its coronavirus vaccine | The Verge


Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven

MarketWatch USA Business November 26, 2022

thumbnailRosenberg has been interviewed many times by Barron’s and has made some prescient calls. In late 2011, he compared (MSFT) favorably to (IBM), which had then drawn a big investment from (BRK.A). “Warren Buffett came pretty late to the IBM party,” he said. Microsoft is up... + más

Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven | MarketWatch

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC


Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven

MarketWatch USA Business November 26, 2022

thumbnailRosenberg has been interviewed many times by Barron’s and has made some prescient calls. In late 2011, he compared (MSFT) favorably to (IBM), which had then drawn a big investment from (BRK.A). “Warren Buffett came pretty late to the IBM party,” he said. Microsoft is up... + más

Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven | MarketWatch

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC


Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CNBC USA Health November 02, 2022

thumbnailPfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch



About iurex | Privacy Policy | Disclaimer |